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Background
New technologies such as next generation sequencing
(NGS) and -omics have changed the way in which cell
line development, cell line engineering and cell culture
R&D are generally performed. However, genomic and
molecular data are often scattered in different locations,
in different formats, and not easily accessible. Addition-
ally, data quality issues may be inadequately tracked,
leading to suboptimal decisions and increasing the risk
of project failure. Complex workflows may require dif-
ferent tools or may not be supported by available soft-
ware solutions.
In order to reduce the time and costs associated with
cell line development and cell culture R&D projects,
intelligent bioinformatics tools and knowledge manage-
ment systems are required ensuring collaboration and
knowledge sharing among research groups and sites.
Results
To address these challenges, we developed a single, inte-
grated knowledge management and analysis platform,
Genedata Selector™ (Figure 1A). The enterprise plat-
form integrates public and proprietary genome and
“omics” data from different sources and is highly scal-
able, being able to handle hundreds of genomes and
related information. Additionally, all publicly available
CHO cell lines and the Chinese hamster genome with
refined gene models, improved functional annotation,
transcription factor binding site and pathway informa-
tion are integrated in this one platform.
Due to this open, integrated and versatile platform for
all NGS and omics technologies, many applications are
supported. This supports streamlining of R&D processes
and makes valuable information (such as genomes, cell
lines and related experimental data) readily accessible to
different teams, thereby avoiding duplication of research
efforts (Figure 1B). To guarantee that the information in
the system is always up to date, numerous different
databases can be automatically scanned, and the infor-
mation updated in the system.
Standardized workflows in the system enable, e.g. the
processing and analysis of RNASeq data, to gene predic-
tion and gene model refinement, and generation of fully
annotated genomes from raw resequencing data. Users
have access to the best gene models for proprietary cell
lines, building the foundation for successful genome-based
R&D. Differences between cell lines on the genome, pro-
tein, pathway level, etc. can be elucidated easily through
interactive analysis tools, enabling the understanding of
the underlying biology through a single, integrated view.
For cell line engineering, sophisticated signaling path-
way analysis tools were integrated in the platform to
enable efficient prioritization of engineering targets for
improving protein production (e.g. focusing on apoptosis
or stress control, protein secretion, glycosylation or gen-
ome stability). When targets have been identified, the
next step is to define the gene editing strategy. Genedata
Selector supports all gene editing technologies. For
instance, CRISPR/Cas9 target sequences can be calcu-
lated in any genome (de novo or resequencing data), and
target gene sequences and uniqueness of editing sites can
be interactively analyzed. Errors during target sequence
design are reduced and the success rate of gene/genome
editing projects can be increased significantly.
Another high-value application, which is now possible
with new NGS technologies, is the accurate determina-
tion of integration sites and the integrity of inserts in
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clones. Here, we have applied the platform to localize
insertions in proprietary gene models through auto-
mated bioinformatics pipelines for processing and analy-
sis of sequencing data. This avoids costly propagation of
clones with wrong/disrupted inserts.
Rational optimization of cell lines, media and process
parameters is another issue which we have addressed.
Integrated genomics/omics data analysis on pathways
are provided in the platform, enabling users to identify
novel relationships in experimental data and to understand
molecular differences between cell lines, cultivation
conditions and time points. In particular, the integrated
view provided through the platform allows the rapid inter-
pretation of complex datasets. This provides strong sup-
port for rational optimization of media and feeds by
facilitating discovery of limitation or accumulation of
metabolites and other key factors which have to be opti-
mized to avoid costly trial and error.
All these applications are supported by an integrated
rich statistical toolbox allowing the easy identification of
biological functions and pathways which show significant
differences between cell lines/clones/process conditions.
Figure 1 A. Scheme of the open and scalable platform, providing a comprehensive view from nucleotides via pathways to patents. B. Excerpt of
applications for cell line development and cell culture R&D supported by the platform.
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Conclusions
We have developed an integrated software platform,
Genedata Selector, to streamline cell line engineering,
cell line development and cell culture optimization R&D
in biopharmaceutical production processes. The platform
helps to reduce the high costs and long development
times currently required for these processes. Designed as
an enterprise system, the platform ensures knowledge
sharing and collaboration among research groups and
sites, avoiding unnecessary duplication of research
efforts. The development of highly competitive proprie-
tary cell lines and processes is supported, increasing the
success rate of R&D projects
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